Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Emerging Strategies for Immunotherapy of Solid Tumors Using Lipid-Based Nanoparticles.
Adv Sci (Weinh)
February 2024
Department of Chemical Engineering, The University of Melbourne, Parkville, Victoria, 3010, Australia.
The application of lipid-based nanoparticles for COVID-19 vaccines and transthyretin-mediated amyloidosis treatment have highlighted their potential for translation to cancer therapy. However, their use in delivering drugs to solid tumors is limited by ineffective targeting, heterogeneous organ distribution, systemic inflammatory responses, and insufficient drug accumulation at the tumor. Instead, the use of lipid-based nanoparticles to remotely activate immune system responses is an emerging effective strategy.
View Article and Find Full Text PDFEstimating kidney function in patients with cancer: A narrative review.
Acta Physiol (Oxf)
June 2023
Department of Medicine, Section on Nephrology, Boston Medical Center, Boston, Massachusetts, USA.
Aim: Accurate evaluation of glomerular filtration rate (GFR) is crucial in Oncology as drug eligibility and dosing depend on estimates of GFR. However, there are no clear guidelines on the optimal method of determining kidney function in patients with cancer. We aimed to summarize the evidence on estimation of kidney function in patients with cancer.
View Article and Find Full Text PDFBiclonal gammopathy of undetermined significance in a patient with systemic lupus erythematosus and antiphospholipid syndrome.
Reumatismo
February 2022
Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, La Sapienza University, Rome.
The case of a patient suffering from systemic lupus erythematosus with associated antiphospholipid antibody syndrome is described. In this patient, on protein electrophoresis, two monoclonal immunoglobulin G λ and k peaks were seen, defining a condition of biclonal gammopathy of undetermined significance (BGUS). This condition is extremely rare, especially in chronic inflammatory rheumatic diseases.
View Article and Find Full Text PDFThe Etiology and Pathophysiology Genesis of Benign Prostatic Hyperplasia and Prostate Cancer: A New Perspective.
Medicines (Basel)
June 2021
Molecular Medicine, NSW Health Pathology, John Hunter Hospital, Newcastle, NSW 2305, Australia.
Background: The etiology of benign prostatic hyperplasia and prostate cancer are unknown, with ageing being the greatness risk factor.
Methods: This new perspective evaluates the available interdisciplinary evidence regarding prostate ageing in terms of the cell biology of regulation and homeostasis, which could explain the timeline of evolutionary cancer biology as degenerative, inflammatory and neoplasm progressions in these multifactorial and heterogeneous prostatic diseases.
Results: This prostate ageing degeneration hypothesis encompasses the testosterone-vascular-inflamm-ageing triad, along with the cell biology regulation of amyloidosis and autophagy within an evolutionary tumorigenesis microenvironment.
Amyloidosis and the risk of cancer: a nationwide population-based study.
Int J Clin Oncol
December 2015
Department of Chest Medicine, Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei, 112, Taiwan.
Background: The association between amyloidosis and cancer remains unclear.
Participants And Methods: Using the Taiwan National Health Insurance Research Database we conducted a population-based cohort study. Patients newly diagnosed with amyloidosis between 1997 and 2009 were enrolled.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!